Videos

KEEPsAKE 1 long-term data confirm sustained MDA responses, structural protection in nearly 9 in 10 patients, and a cardiovascular safety signal that may favor IL-23 inhibition over JAK inhibitors.

Recognition gaps, seronegative disease, and an expanding pipeline define the current Sjögren's moment.

Mease explains the biological rationale behind combining GLP-1 receptor agonist therapy with IL-17 inhibition in patients with PsA and obesity.

Isabelle Peene, MD, PhD, recaps efgartigimod data showing maintained CRESS response and low disease activity through 48 weeks in the Sjögren's disease RHO+ OLE.

Denis Poddubnyy, MD, PhD, MSc, discusses how non-nociceptive pain is an important piece of treating the whole AxSpA picture.

Laura Coates, MBChB, PhD, discusses data showing early separation in ACR50 and disease activity measures at week 4, before substantial weight loss.

Laure Gossec, MD, PhD, discusses new research showing early responders maintain greater patient-reported outcome improvements through year 3.

R. Hal Scofield, MD, discusses exploratory biomarker analyses from DAHLIAS investigating serotype, IFN, and IgG subgroups.

The first phase 3 data for filgotinib in axial spondyloarthritis show early, significant, and durable ASAS40 responses with no new safety signals through 52 weeks.

Xenofon Baraliakos, MD, PhD, discusses significant improvements in BASDAI and ASDAS scores in new late-breaking data from EULAR 2026.

Richard Furie, MD, discusses a post hoc analysis of BLISS-LN showing a markedly slower rate of kidney function loss with belimumab versus PBO.

Anisha Dua, MD, MPH, discusses post hoc data from SELECT-GCA that suggest patients with relapsing disease face substantially higher relapse rates.

James F. Howard JR, MD, discusses the importance of the expanded label of argenx’s efgartigimod alfa (Vyvgart)

May is Lupus Awareness Month and Shivani Garg, MD, PhD, outlines a precision dosing framework that may improve outcomes and reduce toxicity risk in SLE.

Work and activity limitations from arthritis remain far above Healthy People 2030 targets, with the heaviest burden concentrated in populations least likely to access care.

A new-user cohort study found that achieving a serum urate level below 6 mg/dL within 12 months was associated with a 9% relative reduction in MACE over 5 years.

Spatial transcriptomic profiling of synovial tissue identifies a COMP-high fibroblast population in vascular niches as a pre-treatment marker of non-remission.

Extended follow-up from the APIPPRA trial also shows evidence of potentially longer protection in the highest-risk subgroup carrying multiple autoantibodies.

The combination showed efficacy in a predominantly female, treatment-experienced, high-BMI population.

Palumbo discussed how age and disease stage should guide injection decisions in knee OA.

The FDA's 510(k) clearance for updated BEAR Implant labeling marks the first time a sports medicine product has carried a label claim tied to reduced post-traumatic osteoarthritis risk.

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.

Joshi discussed a antibody-free nanoparticle platform that autonomously homes to the most damaged cartilage regions in osteoarthritis.

Fleischmann discussed new modalities emerging in the rheumatology field, with the closest frontier in lupus.

Shenoi discussed what the new juvenile arthritis draft guidelines, presented at ACR 2025, emphasized.

Dua discussed how management of PMR has continued to change over the past couple of years.

Wells and Troum discussed advances in 2025 that are continuing to transform the systemic autoimmune diseases.

Patel shared findings from a retrospective cohort study in people with GPA or MPA at RWCS 2026.

Shenoi discussed how the rheumatology field continues to adapt to workforce shortages.

Troum and Wells discussed how AI tools help clinicians in their practice.